$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
1. Preparation of Skin Fibroblasts for Reprogramming
- Using an automated cell thawing system or a 37 °C water bath, thaw the adult human dermal fibroblasts (aHDFs) and plate 200,000 per T75 flask (count with an automated cell counter) in 10 mL of fibroblast medium (see Table 1) at 37 °C in 5% CO2.
- Perform a complete medium change with fibroblast medium on the next day.
- Change the fibroblast medium every 3–4 days until the cells reach 95% confluency.
NOTE: One confluent flask will contain approximately 1,000,000 cells.
2. Plating for Reprogramming (Day −1)
NOTE: It is recommended to use a gelatin coating for short term experiments (up to 30 days); alternatively, for long term experiments it is recommended to start on a poly-L-ornithine, fibronectin and laminin (PFL) coating.
- 60 min before plating the aHDFs for reprogramming, coat a 24-well plate with 0.1% gelatin (250 µL/well) and incubate at 37 °C.
- Aspirate the fibroblast medium on the aHDFs. Wash once with Dulbecco's phosphate buffer saline (DPBS). Dissociate the cells with 0.05% trypsin (1.5 mL per T75 flask) at 37 °C for 3–5 min.
- Add fibroblast medium to neutralize the trypsin (3 mL per flush per T75 flask) and collect the detached cells in a 15 mL tube by flushing out the cells in the flask twice.
- Spin down the cells at 400 x g for 5 min. Discard supernatant and resuspend the cell pellet in 1 mL of fibroblast medium.
- Count the cells using an automated cell counter (to ensure a good quality conversion check that the cell viability is above 90% with trypan blue staining).
- For a complete 24-well plate, prepare a suspension of 1,320,000 cells in 13.2 mL of fibroblast medium to achieve a suspension of 100,000 cells/mL of medium (or 55,000 cells/well in 550 µL of fibroblast medium multiplied by the number of wells needed).
- Aspirate the gelatin from the plate and wash twice with DPBS. Add 500 µL of the cell suspension to each well and incubate overnight at 37 °C in 5% CO2.
3. Viral Transduction (Day 0)
NOTE: Working with lentiviral particles requires category 2 equipment and the use of an agent to neutralize the virus. Wearing double pairs of gloves is also strongly recommended.
- Warm up 13.2 mL of fibroblast medium to 37 °C.
- Thaw a lentiviral vector containing the transcription factors achaete-scute family bHLH transcription factor 1 (Ascl1) and Brn2 with two short hairpin RNAs (shRNA) targeting RE1-silencing transcription factor (REST) at room temperature.
- Add the necessary volume of lentivirus to infect the aHDFs at multiplicity of infection (MOI) of 20 to the medium without any transduction enhancers.
- Replace the medium in the 24-well plate with fibroblast medium containing the lentiviral vector (500 µL/well) and incubate overnight at 37 °C in 5% CO2.
- The next day, replace the medium in the wells with fresh fibroblast medium without the lentiviral vector.
NOTE: The medium is considered infectious for 7 days and as such, adequate protection and handling procedures should be used during the first week following viral transduction.
4. Maintenance of the Converting Cells
NOTE: Once conversion begins cells are susceptible to lifting; take care to tip the plate up and use a 1,000 µL pipette when removing media to avoid cells detaching.
- On day 3, remove the fibroblast medium and add 500 µL of early neuronal conversion medium (see Table 1).
- Two to three times a week, take out 225 µL of old medium from the well and add-in 250 µL of fresh early neuronal conversion medium.
- On day 18, remove all of the medium from each well and replace with 500 µL of late neuronal conversion medium (see Table 1).
- Continue to change half of the medium as above with late neuronal conversion medium every 2–3 days until day 25 or experiment endpoint (Figure 1A).
Table 1. Composition of the different media used. Full description of the composition for media needed in this protocol including fibroblast medium, early neuronal conversion medium, late neuronal conversion medium.
| Stock Concentration | Working Concentration |
| Fibroblast medium |
| Basal medium | N/A | N/A |
| Penicillin/Streptomycin | 10,000 U/mL | 100 mg/mL |
| FBS | N/A | 10% |
| Early neuronal conversion medium (ENM) | |
| Neural differentiation medium | N/A | N/A |
| Penicillin/Streptomycin | 10,000 U/mL | 100 mg/mL |
| CHIR99021 | 10 mM | 2 µM |
| SB-431542 | 20 mM | 10 µM |
| Noggin | 100 µg/mL | 0.5 µg/mL |
| LDN-1931189 | 10 mM | 0.5 µM |
| VPA | 1 M | 1 mM |
| LM-22A4 | 20 mM | 2 µM |
| GDNF | 20 µg/mL | 2 ng/mL |
| NT3 | 10 µg/mL | 10 ng/µL |
| db-cAMP | 50 mM | 0.5 mM |
| Late neuronal conversion medium (LNM) | |
| Neural differentiation medium | N/A | N/A |
| Penicillin/Streptomycin | 10,000 U/mL | 100 mg/mL |
| LM-22A4 | 20 mM | 2 µM |
| GDNF | 20 µg/mL | 2 ng/mL |
| NT3 | 10 µg/mL | 10 ng/µL |
| db-cAMP | 50 mM | 0.5 mM |
